BridgeBio Oncology Therapeutics, Inc. (BBOT) Current Ratio
- Current ratio · latest quarter: Value 4.69×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.69× | Current assets / current liabilities. $242.38M ÷ $51.63M ≈ 4.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 242.38M USD | Assets, Current |
| Current obligations | 51.63M USD | Liabilities, Current |
| Cash and equivalents | 54.06M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 171.65M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 6.73M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $242.38M | $51.63M | $54.06M | $171.65M | (m) | (m) | $6.73M | (m) | 4.69× |
| 2026-03-31 | $266.50M | $43.26M | $52.66M | $199.62M | (m) | (m) | $12.09M | (m) | 6.16× |
| 2025-12-31 | $432.40M | $35.04M | $373.69M | $51.77M | (m) | (m) | $1.37M | (m) | 12.34× |
| 2025-09-30 | $476.01M | $35.71M | $408.74M | $59.54M | (m) | (m) | $3.65M | (m) | 13.33× |
| 2025-06-30 | $876.78K | $2.63M | (m) | (m) | (m) | (m) | (m) | (m) | 0.33× |
| 2025-03-31 | $1.24M | $1.87M | (m) | (m) | (m) | (m) | (m) | (m) | 0.66× |
| 2024-12-31 | $158.69M | $19.58M | $30.85M | $124.78M | (m) | (m) | $3.07M | (m) | 8.10× |
| 2024-09-30 | $2.04M | $126.69K | (m) | (m) | (m) | (m) | (m) | (m) | 16.12× |
| 2024-06-30 | $2.08M | $79.14K | (m) | (m) | (m) | (m) | (m) | (m) | 26.23× |
| 2024-03-31 | $2.11M | $23.33K | $1.84M | (m) | (m) | (m) | (m) | (m) | 90.42× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |